A patent dispute over the heartburn drug Protonix escalated Monday when Wyeth said it will sue to recover lost profits from sales of Teva Pharmaceutical Industries Ltd.'s generic version.
Teva raised its full-year outlook after announcing its launch of generic equivalents to Wyeth's Protonix, an acid-reflux treatment. Wyeth said it will pursue a patent-infringement claim for lost profits and other damages.